Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 30 of 74

Full-Text Articles in Medicine and Health Sciences

Eribulin Versus Dacarbazine In Patients With Leiomyosarcoma: Subgroup Analysis From A Phase 3, Open-Label, Randomised Study, J. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D. R. D'Adamo, Y. Jia, R. G. Maki Jan 2019

Eribulin Versus Dacarbazine In Patients With Leiomyosarcoma: Subgroup Analysis From A Phase 3, Open-Label, Randomised Study, J. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D. R. D'Adamo, Y. Jia, R. G. Maki

Journal Articles

No abstract provided.


Phase Ii Randomised Discontinuation Trial Of Brivanib In Patients With Advanced Solid Tumours, R. L. Jones, M. J. Ratain, P. J. O'Dwyer, L. L. Siu, J. Jassem, J. Medioni, M. Dejonge, C. Rudin, R. Maki, G. Schwartz, +20 Additional Authors Jan 2019

Phase Ii Randomised Discontinuation Trial Of Brivanib In Patients With Advanced Solid Tumours, R. L. Jones, M. J. Ratain, P. J. O'Dwyer, L. L. Siu, J. Jassem, J. Medioni, M. Dejonge, C. Rudin, R. Maki, G. Schwartz, +20 Additional Authors

Journal Articles

© 2019 The Author(s) Background: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]). Patients and methods: During a 12-week open-label lead-in period, patients received brivanib 800 mg daily and were evaluated for FGF2 status by immunohistochemistry. Patients with stable disease at week 12 were randomised to brivanib or placebo. A study steering committee evaluated week 12 response ...


Complex Karyotype In De Novo Acute Myeloid Leukemia: Typical And Atypical Subtypes Differ Molecularly And Clinically, K. Mrózek, A. K. Eisfeld, J. Kohlschmidt, A. J. Carroll, C. J. Walker, D. Nicolet, J. S. Blachly, M. Bill, J. E. Kolitz, C. D. Bloomfield, +7 Additional Authors Jan 2019

Complex Karyotype In De Novo Acute Myeloid Leukemia: Typical And Atypical Subtypes Differ Molecularly And Clinically, K. Mrózek, A. K. Eisfeld, J. Kohlschmidt, A. J. Carroll, C. J. Walker, D. Nicolet, J. S. Blachly, M. Bill, J. E. Kolitz, C. D. Bloomfield, +7 Additional Authors

Journal Articles

© 2019, Springer Nature Limited. Complex karyotype (CK) with ≥ 3 abnormalities is detected in 10–12% of patients with acute myeloid leukemia (AML) and associated with poor prognosis. The most common unbalanced abnormalities found in CK result in loss of material from the 5q, 7q, and/or 17p chromosome arms. The presence of 5q, 7q, and/or 17p abnormalities denotes typical CK and their absence denotes atypical CK. Since molecular features of CK-AML are not well characterized, we investigated mutational status of 81 leukemia/cancer-associated genes in 160 clinically well-characterized patients. They included 136 patients with ≥ 3 exclusively unbalanced chromosome abnormalities ...


A Phase 1 And Randomized Controlled Phase 2 Trial Of The Safety And Efficacy Of The Combination Of Gemcitabine And Docetaxel With Ontuxizumab (Morab-004) In Metastatic Soft-Tissue Sarcomas, R. L. Jones, S. P. Chawla, S. Attia, P. Schoffski, H. Gelderblom, B. Chmielowski, A. Le Cesne, B. A. Van Tine, J. C. Trent, R. G. Maki, +7 Additional Authors Jan 2019

A Phase 1 And Randomized Controlled Phase 2 Trial Of The Safety And Efficacy Of The Combination Of Gemcitabine And Docetaxel With Ontuxizumab (Morab-004) In Metastatic Soft-Tissue Sarcomas, R. L. Jones, S. P. Chawla, S. Attia, P. Schoffski, H. Gelderblom, B. Chmielowski, A. Le Cesne, B. A. Van Tine, J. C. Trent, R. G. Maki, +7 Additional Authors

Journal Articles

No abstract provided.


Older-Patient-Specific Cancer Trials: A Pooled Analysis Of 2,277 Patients (A151715)., D. Dao, T. Zemla, A. Jatoi, R. A. Freedman, A. Hurria, H. Muss, H. J. Cohen, M. Citron, D. Budman, J. G. Le-Rademacher, +6 Additional Authors Jan 2019

Older-Patient-Specific Cancer Trials: A Pooled Analysis Of 2,277 Patients (A151715)., D. Dao, T. Zemla, A. Jatoi, R. A. Freedman, A. Hurria, H. Muss, H. J. Cohen, M. Citron, D. Budman, J. G. Le-Rademacher, +6 Additional Authors

Journal Articles

BACKGROUND: Less than 3% of older patients with cancer are enrolled in clinical trials. To reverse this underrepresentation, we compared older patients enrolled with older-patient-specific trials, defined as those designed for older patients with cancer, with those enrolled in age-unspecified trials.

MATERIALS AND METHODS: We focused on individual patient data from those ≥65 years (younger patients excluded) and included all Alliance phase III adjuvant breast cancer trials from 1985-2012.

RESULTS: Among 2,277 patients, 1,014 had been enrolled to older-patient-specific and 1,263 to age-unspecified trials. The median age (range) in the older-patient-specific trials was 72 (65-89) years compared ...


Overall Survival And Histology-Specific Subgroup Analyses From A Phase 3, Randomized Controlled Study Of Trabectedin Or Dacarbazine In Patients With Advanced Liposarcoma Or Leiomyosarcoma, S. Patel, M. Von Mehren, D. R. Reed, P. Kaiser, J. Charlson, C. W. Ryan, D. Rushing, M. Livingston, R. G. Maki, G. D. Demetri, +10 Additional Authors Jan 2019

Overall Survival And Histology-Specific Subgroup Analyses From A Phase 3, Randomized Controlled Study Of Trabectedin Or Dacarbazine In Patients With Advanced Liposarcoma Or Leiomyosarcoma, S. Patel, M. Von Mehren, D. R. Reed, P. Kaiser, J. Charlson, C. W. Ryan, D. Rushing, M. Livingston, R. G. Maki, G. D. Demetri, +10 Additional Authors

Journal Articles

No abstract provided.


Probabilistic Modeling Of Personalized Drug Combinations From Integrated Chemical Screen And Molecular Data In Sarcoma, N. E. Berlow, R. Rikhi, M. Geltzeiler, J. Abraham, M. N. Svalina, L. E. Davis, E. Wise, M. Mancini, R. G. Maki, C. Keller, +19 Additional Authors Jan 2019

Probabilistic Modeling Of Personalized Drug Combinations From Integrated Chemical Screen And Molecular Data In Sarcoma, N. E. Berlow, R. Rikhi, M. Geltzeiler, J. Abraham, M. N. Svalina, L. E. Davis, E. Wise, M. Mancini, R. G. Maki, C. Keller, +19 Additional Authors

Journal Articles

No abstract provided.


An Irak1-Pin1 Signalling Axis Drives Intrinsic Tumour Resistance To Radiation Therapy, P. H. Liu, R. B. Shah, Y. Li, A. Arora, P. M. Ung, R. Raman, A. Gorbatenko, S. Kozono, R. G. Maki, S. Sidi, +13 Additional Authors Jan 2019

An Irak1-Pin1 Signalling Axis Drives Intrinsic Tumour Resistance To Radiation Therapy, P. H. Liu, R. B. Shah, Y. Li, A. Arora, P. M. Ung, R. Raman, A. Gorbatenko, S. Kozono, R. G. Maki, S. Sidi, +13 Additional Authors

Journal Articles

No abstract provided.


An Atypical Presentation Of Lichen Planus-Like Reaction From Pembrolizumab., M. Lee, N. Seetharamu Jan 2019

An Atypical Presentation Of Lichen Planus-Like Reaction From Pembrolizumab., M. Lee, N. Seetharamu

Journal Articles

Introduction:With the advent of immunotherapy, a new subtype of side effects called IRAEs or immune related adverse effects have become more common. They may present in various organ systems as colitis, pneumonitis, hypophysitis, and thyroiditis and commonly as dermatological reactions. Case:This is a case report of a lung cancer patient that was started on Pembrolizumab and developed shortly after what appeared to be clinically at first pustular psoriasis but on biopsy was confirmed to be lichen planus. She was discontinued on the Pembrolizumab and treated with both systemic and topical steroids and improved. Conclusion:This case highlights a ...


Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms And Less Complete Recovery At One Year Compared To Unrelated Donors, M. A. Pulsipher, B. R. Logan, D. M. Kiefer, P. Chitphakdithai, M. L. Riches, D. Rizzo, P. Anderlini, R. Bayer, I. Sahdev, B. E. Shaw, +51 Additional Authors Jan 2019

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms And Less Complete Recovery At One Year Compared To Unrelated Donors, M. A. Pulsipher, B. R. Logan, D. M. Kiefer, P. Chitphakdithai, M. L. Riches, D. Rizzo, P. Anderlini, R. Bayer, I. Sahdev, B. E. Shaw, +51 Additional Authors

Journal Articles

No abstract provided.


Radiation Recall Pneumonitis In The Setting Of Immunotherapy And Radiation: A Focused Review, K. Mcgovern, M. Ghaly, M. Esposito, K. Barnaby, N. Seetharamu Jan 2019

Radiation Recall Pneumonitis In The Setting Of Immunotherapy And Radiation: A Focused Review, K. Mcgovern, M. Ghaly, M. Esposito, K. Barnaby, N. Seetharamu

Journal Articles

© 2019 Nagashree Seetharamu. Radiation recall pneumonitis (RRP) is an entity described as pneumonitis localized to a previously irradiated field after exposure to a systemic agent. It has previously been described in the literature in the context of chemotherapeutic agents as well as certain biologics. With immunotherapy taking a more prominent role in the treatment of several different malignancies and its own baseline risk of pneumonitis, it is important to explore the likelihood of RRP, specifically in those patients who have been previously treated with radiation therapy. The current literature regarding RRP with checkpoint inhibitors is reviewed in this article. Alongside ...


Delivering Challenging News: An Illness-Trajectory Communication Curriculum For Multispecialty Oncology Residents And Fellows, D. Cannone, M. Atlas, A. Fornari, M. L. Barilla-Labarca, M. Hoffman Jan 2019

Delivering Challenging News: An Illness-Trajectory Communication Curriculum For Multispecialty Oncology Residents And Fellows, D. Cannone, M. Atlas, A. Fornari, M. L. Barilla-Labarca, M. Hoffman

Journal Articles

Introduction: Published curricula to teach communication skills for postgraduate fellows in oncology are few in number despite the fact that oncologists conduct many difficult discussions with their patients and their families. Such discussions may include disclosing initial diagnosis or relapse of a patient's cancer or relaying a poor prognosis or change to palliative care. Methods: An eight-module course on communication in oncology practice was delivered over 2 months for palliative and oncology fellows and radiation oncology residents. Learners were given a precourse survey in which they were asked to rate their proficiency in various communication tasks. Each learner then ...


Excellent Response To Nivolumab And Ipilimumab In Metastatic Gastroesophageal Junction Squamous Carcinoma., N. Sadagopan, C. Devoe Jan 2019

Excellent Response To Nivolumab And Ipilimumab In Metastatic Gastroesophageal Junction Squamous Carcinoma., N. Sadagopan, C. Devoe

Journal Articles

Unresectable gastroesophageal junction (GEJ) cancers have a poor prognosis and limited treatment options. We report the case of a patient with a Siewert class III gastroesophageal junction squamous carcinoma with metastatic spread into the liver who had an exceptional response to a combination therapy of nivolumab and ipilimumab despite being programmed death-ligand 1 (PD-L1) negative, microsatellite stable (MSS), and having a low tumor mutational burden. He initially experienced disease progression on the chemotherapy regimens modified DCF and FOLFIRI resulting in limited functional status, esophageal stent placement, and feeding tube placement. After about 6 months on nivolumab and ipilimumab, he had ...


Genome-Wide Association Study Identifies An Acute Myeloid Leukemia Susceptibility Locus Near Bicra, C. J. Walker, C. C. Oakes, L. K. Genutis, B. Giacopelli, S. Liyanarachchi, D. Nicolet, A. K. Eisfeld, M. Scholz, J. E. Kolitz, C. D. Bloomfield, +12 Additional Authors Jan 2018

Genome-Wide Association Study Identifies An Acute Myeloid Leukemia Susceptibility Locus Near Bicra, C. J. Walker, C. C. Oakes, L. K. Genutis, B. Giacopelli, S. Liyanarachchi, D. Nicolet, A. K. Eisfeld, M. Scholz, J. E. Kolitz, C. D. Bloomfield, +12 Additional Authors

Journal Articles

No abstract provided.


Nf1 Mutations Are Recurrent In Adult Acute Myeloid Leukemia And Confer Poor Outcome, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, A. Mims, C. J. Walker, J. S. Blachly, D. Nicolet, S. Orwick, J. E. Kolitz, C. D. Bloomfield, +7 Additional Authors Jan 2018

Nf1 Mutations Are Recurrent In Adult Acute Myeloid Leukemia And Confer Poor Outcome, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, A. Mims, C. J. Walker, J. S. Blachly, D. Nicolet, S. Orwick, J. E. Kolitz, C. D. Bloomfield, +7 Additional Authors

Journal Articles

© 2018 Macmillan Publishers Limited, part of Springer Nature Targeted mutation assessment of 81 genes in 1021 adults with de novo acute myeloid leukemia (AML) identified recurrent mutations in the neurofibromin 1 (NF1) gene in 52 (5.1%) patients, including 36 (5.2%) younger and 16 (4.8%) older patients, which suggests NF1 belongs to the 20 most frequently mutated genes in adult AML. NF1 mutations were found throughout the gene, and comprised missense, frameshift, and nonsense mutations. One mutation hotspot, at amino acid threonine 676 (Thr676), was found in 27% of AML patients with NF1 mutations. NF1-mutated patients belonged more ...


Renal Involvement In Chronic Lymphocytic Leukemia., R. Wanchoo, C. Bernabe Ramirez, J. Barrientos, K. D. Jhaveri Jan 2018

Renal Involvement In Chronic Lymphocytic Leukemia., R. Wanchoo, C. Bernabe Ramirez, J. Barrientos, K. D. Jhaveri

Journal Articles

Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in the USA and Western Europe. Kidney disease can present in patients with CLL as a manifestation of the disease process such as acute kidney injury with infiltration or with a paraneoplastic glomerular disease or as a manifestation of extra renal obstruction and tumor lysis syndrome. In the current era of novel targeted therapies, kidney disease can also present as a complication of treatment. Tumor lysis syndrome associated with novel agents such as the B-cell lymphoma 2 inhibitor venetoclax and the monoclonal antibody obinutuzumab are important nephrotoxicities associated with ...


Cpx-351 (Cytarabine And Daunorubicin) Liposome For Injection Versus Conventional Cytarabine Plus Daunorubicin In Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia, J. E. Lancet, G. L. Uy, J. E. Cortes, L. F. Newell, T. L. Lin, E. K. Ritchie, R. K. Stuart, S. A. Strickland, J. E. Kolitz, B. C. Medeiros, +11 Additional Authors Jan 2018

Cpx-351 (Cytarabine And Daunorubicin) Liposome For Injection Versus Conventional Cytarabine Plus Daunorubicin In Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia, J. E. Lancet, G. L. Uy, J. E. Cortes, L. F. Newell, T. L. Lin, E. K. Ritchie, R. K. Stuart, S. A. Strickland, J. E. Kolitz, B. C. Medeiros, +11 Additional Authors

Journal Articles

© 2018 by American Society of Clinical Oncology. Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Patients and Methods In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction ...


Bi-Specific And Tri-Specific Antibodies- The Next Big Thing In Solid Tumor Therapeutics, K. Runcie, D. R. Budman, V. John, N. Seetharamu Jan 2018

Bi-Specific And Tri-Specific Antibodies- The Next Big Thing In Solid Tumor Therapeutics, K. Runcie, D. R. Budman, V. John, N. Seetharamu

Journal Articles

No abstract provided.


Oral Curcumin For Radiation Dermatitis: A Urcc Ncorp Study Of 686 Breast Cancer Patients, J. R. Wolf, C. E. Heckler, J. J. Guido, A. R. Peoples, J. S. Gewandter, M. Ling, V. P. Vinciguerra, T. Anderson, L. Evans, G. R. Morrow, +2 Additional Authors Jan 2018

Oral Curcumin For Radiation Dermatitis: A Urcc Ncorp Study Of 686 Breast Cancer Patients, J. R. Wolf, C. E. Heckler, J. J. Guido, A. R. Peoples, J. S. Gewandter, M. Ling, V. P. Vinciguerra, T. Anderson, L. Evans, G. R. Morrow, +2 Additional Authors

Journal Articles

No abstract provided.


Hybrid Capture–Based Genomic Profiling Of Circulating Tumor Dna From Patients With Advanced Cancers Of The Gastrointestinal Tract Or Anus, A. B. Schrock, D. Pavlick, S. J. Klempner, J. H. Chung, B. Forcier, A. Welsh, L. Young, B. Leyland-Jones, C. Devoe, V. A. Miller, +9 Additional Authors Jan 2018

Hybrid Capture–Based Genomic Profiling Of Circulating Tumor Dna From Patients With Advanced Cancers Of The Gastrointestinal Tract Or Anus, A. B. Schrock, D. Pavlick, S. J. Klempner, J. H. Chung, B. Forcier, A. Welsh, L. Young, B. Leyland-Jones, C. Devoe, V. A. Miller, +9 Additional Authors

Journal Articles

© 2018 American Association for Cancer Research. Purpose: Genomic profiling of tumor biopsies from advanced gastrointestinal and anal cancers is increasingly used to inform treatment. In some cases, tissue biopsy can be prohibitive, and we sought to investigate whether analysis of blood-derived circulating tumor DNA (ctDNA) may provide a minimally invasive alternative. Experimental Design: Hybrid capture–based genomic profiling of 62 genes was performed on blood-based ctDNA from 417 patients with gastrointestinal carcinomas to assess the presence of genomic alterations (GA) and compare with matched tissue samples. Results: Evidence of ctDNA was detected in 344 of 417 samples (82%), and of ...


Chylothorax In Patients With Chronic Lymphocytic Leukemia: A Case Series., D. Sammartino, S. Khanijo, S. Koenig, J. F. Katsetos, A. Tufano, K. R. Rai, J. C. Barrientos Jan 2018

Chylothorax In Patients With Chronic Lymphocytic Leukemia: A Case Series., D. Sammartino, S. Khanijo, S. Koenig, J. F. Katsetos, A. Tufano, K. R. Rai, J. C. Barrientos

Journal Articles

Chylothorax, which is defined as the presence of chyle in the pleural space, is often caused by malignancy. However, chylothorax as a result of underlying CLL is exceedingly rare in the literature. Chyle contains fat soluble vitamins and lymphocytes, meaning that its collection into the pleural space may further exacerbate the immunosupressed state of an individual with CLL. Here, we report three cases of patients with CLL who developed chylothorax, and their management. Chylothorax, although rare with CLL, should be considered in the differential diagnosis when patients with CLL present with pleural effusions, especially if recurrent. Discovery of a chylothorax ...


Extended Follow-Up And Impact Of High-Risk Prognostic Factors From The Phase 3 Resonate Study In Patients With Previously Treated Cll/Sll, J. R. Brown, P. Hillmen, S. O'Brien, J. C. Barrientos, N. M. Reddy, S. E. Coutre, C. S. Tam, S. P. Mulligan, U. Jaeger, J. C. Byrd, +20 Additional Authors Jan 2018

Extended Follow-Up And Impact Of High-Risk Prognostic Factors From The Phase 3 Resonate Study In Patients With Previously Treated Cll/Sll, J. R. Brown, P. Hillmen, S. O'Brien, J. C. Barrientos, N. M. Reddy, S. E. Coutre, C. S. Tam, S. P. Mulligan, U. Jaeger, J. C. Byrd, +20 Additional Authors

Journal Articles

No abstract provided.


Activity Of Pazopanib And Trabectedin In Advanced Alveolar Soft Part Sarcoma, S. Stacchiotti, O. Mir, A. Le Cesne, B. Vincenzi, A. Fedenko, R. G. Maki, N. Somaiah, S. Patel, M. Brahmi, A. Kawai, +13 Additional Authors Jan 2018

Activity Of Pazopanib And Trabectedin In Advanced Alveolar Soft Part Sarcoma, S. Stacchiotti, O. Mir, A. Le Cesne, B. Vincenzi, A. Fedenko, R. G. Maki, N. Somaiah, S. Patel, M. Brahmi, A. Kawai, +13 Additional Authors

Journal Articles

No abstract provided.


Discovery And Functional Implications Of A Mir-29b-1/Mir-29a Cluster Polymorphism In Acute Myeloid Leukemia, A. Ngankeu, P. Ranganathan, V. Havelange, D. Nicolet, S. Volinia, B. L. Powell, J. E. Kolitz, G. L. Uy, R. M. Stone, R. Garzon, +4 Additional Authors Jan 2018

Discovery And Functional Implications Of A Mir-29b-1/Mir-29a Cluster Polymorphism In Acute Myeloid Leukemia, A. Ngankeu, P. Ranganathan, V. Havelange, D. Nicolet, S. Volinia, B. L. Powell, J. E. Kolitz, G. L. Uy, R. M. Stone, R. Garzon, +4 Additional Authors

Journal Articles

© Ngankeu et al. We previously reported that microRNA (miR)-29b is down-regulated and has a tumor suppressor role in acute myeloid leukemia (AML). However, little is known about the mechanisms responsible for miR-29b expression downregulation in AML. In this work we screened for mutations that could affect miR-29b expression. Using Sanger sequencing, we identified a germline thymidine (T) base deletion within the miR-29b-1/miR-29a cluster precursor in 16% of AML patients. Remarkably we found a significant enrichment for the presence of the miR-29 polymorphism in core binding factor (CBF) newly diagnosed AML patients (n = 61/303; 20%) with respect to ...


Merkel Cell Carcinoma Masquerading As Cellulitis: A Case Report And Review Of The Literature, F. Safa, M. Pant, C. Weerasinghe, R. Felix, T. Terjanian Jan 2018

Merkel Cell Carcinoma Masquerading As Cellulitis: A Case Report And Review Of The Literature, F. Safa, M. Pant, C. Weerasinghe, R. Felix, T. Terjanian

Journal Articles

© 2018 Multimed Inc. Merkel cell carcinoma (MCC) is an uncommon malignancy of the skin arising from cells located in the deeper layers of the epidermis called Merkel cells. This malignancy rarely presents as a metastatic disease, and the field is therefore deficient in regards to management. We report the case of a 49-year-old woman who presented with a presumptive diagnosis of osteomyelitis of the left fifth digit that was resistant to treatment with antibiotics; she underwent debridement of the digit that revealed MCC and was later to have metastatic disease to her lungs, liver, and musculoskeletal system. The management of ...


Mutation Patterns Identify Adult Patients With De Novo Acute Myeloid Leukemia Aged 60 Years Or Older Who Respond Favorably To Standard Chemotherapy: An Analysis Of Alliance Studies, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, J. S. Blachly, C. J. Walker, D. Nicolet, S. Orwick, S. E. Maharry, J. E. Kolitz, C. D. Bloomfield, +6 Additional Authors Jan 2018

Mutation Patterns Identify Adult Patients With De Novo Acute Myeloid Leukemia Aged 60 Years Or Older Who Respond Favorably To Standard Chemotherapy: An Analysis Of Alliance Studies, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, J. S. Blachly, C. J. Walker, D. Nicolet, S. Orwick, S. E. Maharry, J. E. Kolitz, C. D. Bloomfield, +6 Additional Authors

Journal Articles

© 2018 Macmillan Publishers Limited, part of Springer Nature. Thus far, only 5-15% of AML patients aged ≥60 years are cured with chemotherapy. Identification of patients who are less (more) likely to respond to standard chemotherapy might enable early risk stratification toward alternative treatment regimens. We used a next-generation sequencing panel of 80 cancer- and/or leukemia-associated genes to profile molecularly 423 older patients with de novo AML. Using variables identified in multivariable models and co-occurring mutations in NPM1-mutated AML, we classified the patients into good-, intermediate-, and poor-risk groups for complete remission (CR) attainment, disease-free (DFS), and overall survival (OS ...


Repurposing Mebendazole As A Replacement For Vincristine For The Treatment Of Brain Tumors, M. De Witt, A. Gamble, D. Hanson, D. Markowitz, C. Powell, S. Al Dimassi, M. Atlas, J. Boockvar, R. Ruggieri, M. Symons Jan 2017

Repurposing Mebendazole As A Replacement For Vincristine For The Treatment Of Brain Tumors, M. De Witt, A. Gamble, D. Hanson, D. Markowitz, C. Powell, S. Al Dimassi, M. Atlas, J. Boockvar, R. Ruggieri, M. Symons

Journal Articles

No abstract provided.


Acalabrutinib (Acp-196) In Relapsed Chronic Lymphocytic Leukemia, J. C. Byrd, B. Harrington, S. O'Brien, J. A. Jones, A. Schuh, S. Devereux, J. Chaves, W. G. Wierda, J. C. Barrientos, R. R. Furman, +20 Additional Authors Jan 2016

Acalabrutinib (Acp-196) In Relapsed Chronic Lymphocytic Leukemia, J. C. Byrd, B. Harrington, S. O'Brien, J. A. Jones, A. Schuh, S. Devereux, J. Chaves, W. G. Wierda, J. C. Barrientos, R. R. Furman, +20 Additional Authors

Journal Articles

Background Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors. Methods In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib. Patients were treated with acalabrutinib at a dose of ...


Relationship Between Obesity And Clinical Outcome In Adults With Acute Myeloid Leukemia: A Pooled Analysis From Four Calgb (Alliance) Clinical Trials, J. J. Castillo, F. Mulkey, S. Geyer, J. E. Kolitz, W. Blum, B. L. Powell, S. L. George, R. A. Larson, R. M. Stone Jan 2016

Relationship Between Obesity And Clinical Outcome In Adults With Acute Myeloid Leukemia: A Pooled Analysis From Four Calgb (Alliance) Clinical Trials, J. J. Castillo, F. Mulkey, S. Geyer, J. E. Kolitz, W. Blum, B. L. Powell, S. L. George, R. A. Larson, R. M. Stone

Journal Articles

Obesity has been previously suggested as an adverse prognostic marker in patients with acute leukemia. To evaluate the relationship between obesity and clinical outcome, disease-free survival (DFS) and overall survival (OS), in patients with acute myelogenous leukemia (AML), including acute promyelocytic leukemia (APL), we performed a pooled analysis of four CALGB (Alliance) clinical trials. Our study included 446 patients with APL from CALGB 9710, and 1,648 patients between 18 and 60 years of age with non-APL AML from CALGB 9621, 10503, and 19808. Obesity was defined as BMI >/=30 kg/m(2) . Multivariate Cox proportional-hazard regression models were fitted ...


A Phase Ii Randomized Trial Comparing Standard And Low Dose Rituximab Combined With Alemtuzumab As Initial Treatment Of Progressive Chronic Lymphocytic Leukemia In Older Patients: A Trial Of The Ecog-Acrin Cancer Research Group (E1908), C. S. Zent, X. V. Wang, R. P. Ketterling, C. A. Hanson, E. N. Libby, J. C. Barrientos, T. G. Call, J. E. Chang, J. J. Liu, M. S. Tallman, +5 Additional Authors Jan 2016

A Phase Ii Randomized Trial Comparing Standard And Low Dose Rituximab Combined With Alemtuzumab As Initial Treatment Of Progressive Chronic Lymphocytic Leukemia In Older Patients: A Trial Of The Ecog-Acrin Cancer Research Group (E1908), C. S. Zent, X. V. Wang, R. P. Ketterling, C. A. Hanson, E. N. Libby, J. C. Barrientos, T. G. Call, J. E. Chang, J. J. Liu, M. S. Tallman, +5 Additional Authors

Journal Articles

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients requiring initial therapy are often older and frailer and unsuitable candidates for standard chemoimmunotherapy regimens. Shorter duration combination monoclonal antibody (mAb) therapy using alemtuzumab and rituximab has been shown to be effective and tolerable treatment for CLL. Standard dose anti-CD20 mAb therapy causes loss of CD20 expression by surviving CLL cells, which can be minimized by decreasing the mAb dose. We report a randomized phase II clinical trial enrolling older (>/= 65 years) patients (median age 76 years, n=31) with treatment naive progressive CLL. Patients received 8-12 weeks of standard subcutaneous alemtuzumab ...